Funding News Edition: July 01, 2020 See more articles in this edition
Operation Warp Speed is a partnership among several federal government agencies to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics, including the specific goal of delivering 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.
Notably, Operation Warp Speed will manufacture promising candidate vaccines at an industrial scale before efficacy and safety are confirmed through Phase III trials. Doing so will significantly shorten the timeline for distribution as compared to traditional vaccine development, should the trials succeed.
NIAID is engaging established clinical trial networks to support Operation Warp Speed. We have no funding opportunities tied specifically to Operation Warp Speed, although we have many ongoing initiatives that support COVID-19 research—see Coronaviruses: Information for Researchers.
Read Fact Sheet: Explaining Operation Warp Speed to learn more about the program.